SNHG3 is generally upregulated in multiple malignancies, including bladder cancer [6, 7], breast cancer [8–11], clear cell renal cell carcinoma [12, 13], colorectal cancer [14, 15], esophageal carcinoma [16], gastric cancer [17–19], glioma [20, 21], hepatocellular carcinoma [22], laryngeal squamous cell carcinoma [23], lung cancer [24, 25], osteosarcoma [26], ovarian [27–29], and prostate cancer [30–32] (Table 1). Here, SNHG3 is linked to urinary bladder carcinoma.